Lumera Receives Purchase Order from HMS for a ProteomicProcessor Biosensor
News May 05, 2006
Lumera Corporation has announced that it had received a purchase order from Harvard Medical School (HMS) for its beta ProteomicProcessor™ Biosensor instrument.
"To have an organization of Harvard Medical School's standing purchase one of our beta instruments is extremely gratifying," said Dr. Tim Londergan, Director of Lumera's Bioscience Business Unit.
"We look forward to demonstrating our instrument's capability with Dr. LaBaer's cancer biomarker platform and believe that data from this collaboration will enhance our value proposition with pharmaceutical customers."
As previously announced, Lumera's strategy in this arena is to place five beta units with highly respected, world renowned research organizations to demonstrate and establish new applications, which take advantage of the instrument's unprecedented throughput.
This purchase order from HMS is the second placement of the biosensor.
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE